(Q46204430)

20 December 2017

title

Mixed results with modulation of TH-17 cells in human autoimmune diseases (English)

1 reference

20 December 2017

author name string

Lawrence Steinman

series ordinal

1

1 reference

20 December 2017

language of work or name

English

0 references

publication date

17 December 2009

1 reference

20 December 2017

published in

Nature Immunology

1 reference

20 December 2017

volume

11

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

41-44

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/ni.1803

exact match

0 references

cites work

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes

21 January 2018

1 reference

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis

21 January 2018

1 reference

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

21 January 2018

1 reference

12 December 2020

Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

1 reference

12 December 2020

Phenotypic and functional features of human Th17 cells

1 reference

12 December 2020

From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited

1 reference

12 December 2020

Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system

1 reference

12 December 2020

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

12 December 2020

Plasma osteopontin levels in multiple sclerosis.

1 reference

12 December 2020

T(H)-17 cells in the circle of immunity and autoimmunity

1 reference

12 December 2020

Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia.

1 reference

12 December 2020

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.

1 reference

12 December 2020

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

1 reference

12 December 2020

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

1 reference

12 December 2020

Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion

1 reference

12 December 2020

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

1 reference

12 December 2020

A rush to judgment on Th17

1 reference

12 December 2020

Primer: inflammasomes and interleukin 1beta in inflammatory disorders

1 reference

12 December 2020

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

1 reference

12 December 2020

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

1 reference

12 December 2020

Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.

1 reference

12 December 2020

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

1 reference

12 December 2020

Structure and signalling in the IL-17 receptor family

1 reference

12 December 2020

Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).

1 reference

12 December 2020

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

12 December 2020

Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody

1 reference

12 December 2020

Elevated osteopontin levels in active relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN

1 reference

12 December 2020

Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

A molecular trio in relapse and remission in multiple sclerosis

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Therapy: Targeted but not trouble-free: efalizumab and PML

1 reference

12 December 2020

Design of effective immunotherapy for human autoimmunity

1 reference

12 December 2020

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

12 December 2020

IL-23/IL-17 immunity as a hallmark of Crohn's disease

1 reference

12 December 2020

Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells.

1 reference

12 December 2020

Humanized antihuman IL-6 receptor antibody, tocilizumab

1 reference

12 December 2020

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

12 December 2020

Multiple sclerosis: a two-stage disease

1 reference

12 December 2020

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

12 December 2020

Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system

1 reference

12 December 2020

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

1 reference

12 December 2020

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

12 December 2020

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

12 December 2020

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells

1 reference

12 December 2020

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

1 reference

12 December 2020

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

1 reference

12 December 2020

Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NI.1803

1 reference

20 December 2017

Dimensions Publication ID

1037410376

0 references

1 reference

20 December 2017